Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

NCT01837641 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01837641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
May 3, 2013
Completion date
August 24, 2016
Enrollment
63 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease